Self-monitoring Blood Glucose Devices Market (By Product: Testing Strips, Self-Monitoring Blood Glucose (SMBG) Meters, Continuous Glucose Monitors, lancets; By Application: Type 2 Diabetes, Type 1 Diabetes, Gestational Diabetes) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2034
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Self-monitoring Blood Glucose Devices Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Self-monitoring Blood Glucose Devices Market Revenue and Volume, By Product, 2024-2033
8.1.1 Testing Strips
8.1.1.1. Market Revenue and Volume Forecast (2021-2033)
8.1.2. Self-Monitoring Blood Glucose (SMBG) Meters
8.1.2.1. Market Revenue and Volume Forecast (2021-2033)
8.1.3. Continuous Glucose Monitors
8.1.3.1. Market Revenue and Volume Forecast (2021-2033)
8.1.4. lancets
8.1.4.1. Market Revenue and Volume Forecast (2021-2033)
9.1. Self-monitoring Blood Glucose Devices Market Revenue and Volume, By Application, 2024-2033
9.1.1. Type 2 Diabetes
9.1.1.1. Market Revenue and Volume Forecast (2021-2033)
9.1.2. Type 1 Diabetes
9.1.2.1. Market Revenue and Volume Forecast (2021-2033)
9.1.3. Gestational Diabetes
9.1.3.1. Market Revenue and Volume Forecast (2021-2033)
10.1. North America
10.1.1. Market Revenue and Volume Forecast, By Product (2021-2033)
10.1.2. Market Revenue and Volume Forecast, By Application (2021-2033)
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, By Product (2021-2033)
10.1.3.2. Market Revenue and Volume Forecast, By Application (2021-2033)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, By Product (2021-2033)
10.1.4.2. Market Revenue and Volume Forecast, By Application (2021-2033)
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, By Product (2021-2033)
10.2.2. Market Revenue and Volume Forecast, By Application (2021-2033)
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, By Product (2021-2033)
10.2.3.2. Market Revenue and Volume Forecast, By Application (2021-2033)
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, By Product (2021-2033)
10.2.4.2. Market Revenue and Volume Forecast, By Application (2021-2033)
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, By Product (2021-2033)
10.2.5.2. Market Revenue and Volume Forecast, By Application (2021-2033)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, By Product (2021-2033)
10.2.6.2. Market Revenue and Volume Forecast, By Application (2021-2033)
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, By Product (2021-2033)
10.3.2. Market Revenue and Volume Forecast, By Application (2021-2033)
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, By Product (2021-2033)
10.3.3.2. Market Revenue and Volume Forecast, By Application (2021-2033)
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, By Product (2021-2033)
10.3.4.2. Market Revenue and Volume Forecast, By Application (2021-2033)
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, By Product (2021-2033)
10.3.5.2. Market Revenue and Volume Forecast, By Application (2021-2033)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, By Product (2021-2033)
10.3.6.2. Market Revenue and Volume Forecast, By Application (2021-2033)
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, By Product (2021-2033)
10.4.2. Market Revenue and Volume Forecast, By Application (2021-2033)
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, By Product (2021-2033)
10.4.3.2. Market Revenue and Volume Forecast, By Application (2021-2033)
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, By Product (2021-2033)
10.4.4.2. Market Revenue and Volume Forecast, By Application (2021-2033)
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, By Product (2021-2033)
10.4.5.2. Market Revenue and Volume Forecast, By Application (2021-2033)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, By Product (2021-2033)
10.4.6.2. Market Revenue and Volume Forecast, By Application (2021-2033)
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, By Product (2021-2033)
10.5.2. Market Revenue and Volume Forecast, By Application (2021-2033)
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, By Product (2021-2033)
10.5.3.2. Market Revenue and Volume Forecast, By Application (2021-2033)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, By Product (2021-2033)
10.5.4.2. Market Revenue and Volume Forecast, By Application (2021-2033)
11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Bionime Corporation
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. B. Braun Melsungen AG
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. F. Hoffmann-La Roche Ltd.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. LifeScan IP Holdings, LLC
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. PHC Holdings Corporation
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Terumo Corporation
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Trividia Health, Inc. (Sinocare Inc.)
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. ARKRAY, Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Ypsomed Holding AG
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample